Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion

被引：38

作者：

Fenaux, Pierre ^{[1
,2
]}

Bowen, David ^{[3
]}

Gattermann, Norbert ^{[4
]}

Hellstrom-Lindberg, Eva ^{[5
]}

Hofmann, Wolf-Karsten ^{[6
]}

Pfeilstoecker, Michael ^{[7
]}

Sanz, Guillermo ^{[8
]}

Santini, Valeria ^{[9
]}

机构：

[1] Hop Avicenne, AP HP, F-93009 Bobigny, France

[2] Univ Paris 13, Bobigny, France

[3] Leeds Teaching Hosp, Leeds, W Yorkshire, England

[4] Univ Dusseldorf, Dusseldorf, Germany

[5] Huddinge Univ Hosp, Karolinska Inst, S-14186 Huddinge, Sweden

[6] Univ Hosp Mannheim, Berlin, Germany

[7] Hanusch Hosp, Vienna, Austria

[8] Hosp Univ La Fe, Valencia, Spain

[9] Careggi Hosp, Florence, Italy

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 11期

关键词：

Myelodysplastic syndromes; MDS; Azacitidine; Recommendations; Int-2; High-risk; CONVENTIONAL CARE REGIMENS; PROGNOSTIC SCORING SYSTEM; WORLD-HEALTH-ORGANIZATION; RANDOMIZED PHASE-III; DNA METHYLATION; ACUTE-LEUKEMIA; CLASSIFICATION; CANCER; AZACYTIDINE; SURVIVAL;

D O I：

10.1016/j.leukres.2010.05.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1410 / 1416

页数：7

共 43 条

[1]

[Anonymous], 2021, PLYM M PA

[2] International prognostic scoring system and other prognostic systems for myelodysplastic syndromes [J].

Balduini, CL ;

Guarnone, R ;

Pecci, A ;

Centenara, E ;

Ascari, E .

BLOOD, 1997, 90 (10) :4232-4233

[3]

BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[4] Azacitidine for the treatment of myelodysplastic syndrome [J].

Cataldo, Vince D. ;

Cortes, Jorge ;

Quintas-Cardama, Alfonso .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) :875-884

[5]

*CELG EUR LTD, 2008, VID SUMM PROD CHAR

[6] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Gattermann, Norbert ;

Germing, Ulrich ;

Sanz, Guillermo ;

List, Alan F. ;

Gore, Steven ;

Seymour, John F. ;

Dombret, Herve ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :562-569

[7] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[8] 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation [J].

Field, T. ;

Perkins, J. ;

Huang, Y. ;

Kharfan-Dabaja, M. A. ;

Alsina, M. ;

Ayala, E. ;

Fernandez, H. F. ;

Janssen, W. ;

Lancet, J. ;

Perez, L. ;

Sullivan, D. ;

List, A. ;

Anasetti, C. .

BONE MARROW TRANSPLANTATION, 2010, 45 (02) :255-260

[9]

Garcia-Manero G, 2009, BLOOD, V114, P801

[10] A Phase II Study of Post-Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study [J].

Gardin, Claude ;

Prebet, Thomas ;

Bouabdallah, Krimo ;

Caillot, Denis ;

Guerci, Agnes ;

Raffoux, Emmanuel ;

Marolleau, Jean Pierre ;

Pautas, Cecile ;

Banos, Anne ;

Himberlin, Chantal ;

Taksin, Anne-Laure ;

Pigneux, Arnaud ;

Thomas, Xavier ;

Jernival, Tony ;

Vey, Norbert ;

Dreyfus, Francois ;

Chevret, Sylvie ;

Dombret, Herve ;

Fenaux, Pierre .

BLOOD, 2009, 114 (22) :348-348

← 1 2 3 4 5 →